Fluicell

34,50 SEK

+12,38 %

Mindre end 1K følgere

FLUI

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+12,38 %
+161,36 %
+213,64 %
+245,00 %
+202,63 %
+200,00 %
-80,51 %
-97,95 %
-96,88 %

Fluicell operates in biotechnology. The company conducts research and development in the processing of cell composition in the development of new drugs. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and ultimately process cells. In addition, there is expertise in 2D/3D printing. Fluicell was founded in 2012 and is headquartered in Gothenburg.

Læs mere
Markedsværdi
47,39 mio. SEK
Aktieomsætning
988,37 t SEK
Omsætning
6 mio.
EBIT %
-139,87 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
3.6
2026

Generalforsamling '26

14.8
2026

Delårsrapport Q2'26

13.11
2026

Delårsrapport Q3'26

ViserAlle indholdstyper
Eksterne analyser

Fluicell: Accelerating Towards further Milestones - Analyst Group

Fluicell AB (publ) (”Fluicell” or “the Company”) offers innovative R&D instruments for both single-cell analysis and 3D bioprinting business segments in which we forecast will enter a fast-growing pace, where a revenue of SEK 68.6m is estimated for the...

Fluicell

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

Fluicell : Ready to Intensify Sales Activities - Analyst Group

Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter a fast-growth pace, where a revenue of SEK 68.6m is estimated for the year 2026. Based on an applied P/S-multiple of ...

Fluicell
Eksterne analyser

Fluicell: Comment, Q3-22 Report - Analyst Group

Summary of Operating Activities During Q3-22, the revenue amounted to SEK 0.51m, compared to SEK 1.1m in Q3-21, which corresponds to a YoY decrease of 52%. Compared to the previous quarter of Q2-22 where the revenue amounted to SEK 0.49m, the increase...

Fluicell
Eksterne analyser

Fluicell: Clinical Results on the Horizon - Analyst Group

Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter a fast-growth pace, where a revenue of SEK 68.6m is estimated for the year 2026. Based on an applied P/S-multiple of ...

Fluicell
Eksterne analyser

Analyst Group Initiates Equity Research Coverages of Fluicell

Our analyst summarizes the investment case:“Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter into a fast-growth pace, where a revenue of SEK 68.6M is estimated for the...

Fluicell

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.